Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Maravai LifeSciences Holdings, Inc. - Class A common stock (NQ:MRVI)

6.230 -0.010 (-0.16%)
Streaming Delayed Price Updated: 3:32 PM EDT, Jul 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Maravai LifeSciences Holdings, Inc. - Class A common stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
News headline image
Crispr Therapeutics Stock Sees Improved Relative Strength Rating ↗
Crispr Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 68 to 74. 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 14) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
News headline image
Novan Stock Joins Elite Club Of Stocks With RS Ratings Over 90 ↗
Novan shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
News headline image
Earnings Scheduled For May 10, 2021 ↗
Companies Reporting Before The Bell • Revlon (NYSE:REV) is likely to report earnings for its first quarter. • Bluegreen Vacations (NYSE:BVH) is expected to report... 
Via Benzinga
News headline image
Twist Bioscience Stock Hits 80-Plus Relative Strength Rating Benchmark ↗
TwistBioscienceCorp shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82. 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 10) Alexion Pharmaceuticals,... 
Via Benzinga
News headline image
BioNTech SE Stock Earns Membership In 95-Plus Composite Rating Club ↗
The IBD SmartSelect Composite Rating for BioNTech SE stock rose from 94 to 97 Thursday. The Covid-19 vaccine stock also has 98 Relative Strength Rating. 
Via Investor's Business Daily
News headline image
Supernus Pharmaceuticals Stock Getting Closer To Key Technical Measure ↗
A Relative Strength Rating upgrade for Supernus Pharmaceuticals shows improving technical performance. Will it continue? 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 7) Agios Pharmaceuticals, Inc... 
Via Benzinga
News headline image
BridgeBio Stock Flashes Healthy 83 RS Rating ↗
Look for stocks with a Relative Strength Rating of 80 or higher. BridgeBio stock just hit that mark, with a jump from 79 to 83 Wednesday. 
Via Investor's Business Daily
News headline image
Twist Bioscience Stock Scores Relative Strength Rating Upgrade ↗
When adding stocks to your watch list, look for stocks with an 80 or higher RS Rating. Twist Bioscience just met that criteria with a new score of 84. 
Via Investor's Business Daily
News headline image
Cel-Sci Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating ↗
Cel-Sci stock saw an improvement to its Relative Strength Rating on Thursday, rising from 79 to 87, making the stock a potential watchlist candidate. 
Via Investor's Business Daily
News headline image
Kalvista Pharmaceuticals Stock Shows Rising Relative Strength ↗
A Relative Strength Rating upgrade for Kalvista Pharmaceuticals shows improving technical performance. 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: Iovance To Delay Regulatory Filing For Cancer Therapy, Departures At Passage Bio, Positive Readout For Silence Therapeutics ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18) Alexion Pharmaceuticals, Inc... 
Via Benzinga
News headline image
Horizon Therapeutics Stock Flashes Improved Technical Strength; Nears Buy Point ↗
Horizon Therapeutics stock had its Relative Strength Rating upgraded to 75 -- a welcome improvement, but still shy of the 80 or better score you look for. 
Via Investor's Business Daily
News headline image
Biotech Zai Lab Stock Sees Relative Strength Rating Jump To 83 ↗
A Relative Strength Rating upgrade for ZaiLabLimited shows improving technical performance. 
Via Investor's Business Daily
News headline image
Stock Market Rally Struggles With Inflation Spike; Tesla Sales Fall, Elon Musk Turns On Bitcoin As Coinbase Reports ↗
The market rally tested key levels as inflation fears mounted. Tesla's China sales dived as CEO Elon Musk dissed Bitcoin. 
Via Investor's Business Daily
News headline image
Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2021 Earnings Call Transcript ↗
MRVI earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
IPO Stock Maravai Lifesciences Crushes First-Quarter Forecasts ↗
Late Monday, Maravai reported adjusted income of 26 cents per share on $148.21 million in sales. But the fresh IPO stock was unmoved in after-hours trading. 
Via Investor's Business Daily
Topics Initial Public Offering
News headline image
Coronavirus Vaccine Plays Moderna, Maravai, West Pharmaceutical Among 5 Stocks Near Buy Points ↗
Coronavirus vaccine maker Moderna and vaccine suppliers Maravai and West Pharmaceutical are among five stocks near buy points. 
Via Investor's Business Daily
Topics Supply Chain
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.